智通财经APP获悉，1月12日晚间，药明康德(603259.SH/02359)披露了其2025年度预增公告。公告显示，公司预计全年营业收入约456.56亿元，同比增长约 15.84%；其中持续经营业务收入同比增长约21.4%。盈利方面，经调整non-IFRS归母净利润、归母净利润、扣非归母净利润分别同比增长约41.33%、 102.65%及32.56%，基本每股收益同样翻倍达到6.7元。 在归母净利润、每股收益达成新高的背景下，药明康德2025年度现金分红亦有望创下新高。按照此前，公司在三季度业绩交流会上曾表示，上市以来一贯维 持约30%的现金分红比例。根据本次预告的归母净利润测算，2025年度现金分红总额预计将突破57亿元。 根据统计，上市以来的七年时间里，药明康德通过现金分红、回购及注销股份的方式，累计回馈投资者达到200亿元，超过了公司过去七年累计净利润的 40%。 ...

智通财经APP获悉，2026年1月12日晚间，药明康德(603259.SH/02359)发布了2025年度业绩预增公告。公司预计2025年全年营业收入约454.56亿元，创下历 史新高。 除了创记录的营业收入，药明康德的利润层面，三个口径下关键指标亦实现高于营收的增速攀升，经调整non-IFRS归母净利润、归母净利润及扣非后归母净 利润，分别同比增长约41.33%、102.65%及32.56%。 此前，药明康德已在三季度时第二次上调了全年经营目标。公司表示，紧抓客户需求、业务模式和管理执行的确定性，进一步上调全年业绩指引，预计2025 年持续经营业务重回双位数增长，增速上调至17~18%，公司整体收入上调至435~440亿元。 ...

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology sector [4]. Core Insights - The brain-computer interface (BCI) sector is showing active performance, with recommendations to continue monitoring thematic opportunities. The global BCI market is projected to reach USD 7.63 billion by 2029, indicating a rapidly opening blue ocean market [20][21]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, focusing on innovative drug chains and medical devices. Key recommendations include companies involved in BD overseas acceleration and high-end medical devices [23][25]. Summary by Sections Market Review - The A-share pharmaceutical and biotechnology index rose by 7.81%, outperforming the CSI 300 index by 5.03 percentage points and the ChiNext index by 2.10 percentage points, ranking 6th among 31 sub-industries. The Hong Kong Hang Seng Healthcare Index increased by 10.26%, surpassing the Hang Seng Index by 11.57 percentage points [15][9]. R&D Progress - Recent clinical applications include IMM2510 and Tida-Paclitaxel from Yiming Anke, with ongoing Phase III trials for Tiengoteini from Yaokang and Phase II trials for SYS6017 from Shiyao Group [28]. Key Recommendations - Focus on three categories of companies: 1. Medical scene integrators (e.g., Xiangyu Medical, Weisi Medical) benefiting from insurance payment integration and existing rehabilitation needs [21]. 2. Leaders in invasive/semi-invasive technologies (e.g., Xinwei Medical, Jieti Medical) with significant technological advantages [21]. 3. Full-process support providers (e.g., Meihua Medical, Sanbo Neuroscience) focusing on high-certainty segments like supply chain production and clinical development [21]. Financial Forecasts and Valuations - Key companies and their projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2024-2026 include: - Tianzhili: EPS of 0.64, PE of 24 [3]. - Innovent Biologics: EPS of -0.06, PE of NA [3]. - WuXi AppTec: EPS of 3.27, PE of 30 [3]. - Mindray Medical: EPS of 9.62, PE of 21 [3]. - Weisi Medical: EPS of 1.06, PE of 62 [3]. Policy and Industry Resonance - The report highlights a structural shift in domestic policies favoring innovative drugs, with a focus on clinical value and the potential for valuation recovery in the pharmaceutical sector. The report suggests that the investment attractiveness of the pharmaceutical sector will continue to grow [23][24].

Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, indicating strong financial performance and commitment to shareholder value through significant cash dividends [1] Financial Performance - The company announced that its revenue and profit metrics have reached historical highs, with basic earnings per share doubling to 6.70 yuan per share [1] - The expected net profit attributable to shareholders for 2025 is projected to exceed 57 billion yuan, leading to record cash dividends for shareholders [1] Shareholder Value - WuXi AppTec has maintained a leading cash dividend payout ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The company plans to unlock a total of 2.5 billion Hong Kong dollars in H-share incentives, contingent upon achieving specific revenue targets [1] Incentive Plans - The core unlocking conditions for the 2025 H-share incentive trust plan have been met, with revenue targets set at 42 billion yuan and 43 billion yuan for additional stock grants [1] - The incentive plan aims to foster long-term development and alignment of interests between core talent and the company [1]

根据统计，上市以来的七年时间里，药明康德通过现金分红、回购及注销股份的方式，累计回馈投资者 达到200亿元，超过了公司过去七年累计净利润的40%。 在归母净利润、每股收益达成新高的背景下，药明康德2025年度现金分红亦有望创下新高。按照此前， 公司在三季度业绩交流会上曾表示，上市以来一贯维持约30%的现金分红比例。根据本次预告的归母净 利润测算，2025年度现金分红总额预计将突破57亿元。 智通财经APP获悉，1月12日晚间，药明康德(603259.SH/02359)披露了其2025年度预增公告。公告显 示，公司预计全年营业收入约456.56亿元，同比增长约15.84%；其中持续经营业务收入同比增长约 21.4%。盈利方面，经调整non-IFRS归母净利润、归母净利润、扣非归母净利润分别同比增长约 41.33%、102.65%及32.56%，基本每股收益同样翻倍达到6.7元。 ...

Group 1 - The core viewpoint of the article is that WuXi AppTec (603259.SH/02359) has announced a significant increase in its revenue forecast for the year 2025, projecting approximately 45.456 billion yuan, marking a historical high [1] - The company has raised its annual performance guidance for the second time in the third quarter, indicating a strong focus on customer demand, business model, and management execution certainty [1] - WuXi AppTec expects its continuous operating business to return to double-digit growth, with an adjusted growth rate of 17-18%, and overall revenue revised to 43.5-44 billion yuan [1] Group 2 - In terms of profitability, key indicators under three metrics are expected to grow at a rate higher than revenue, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit attributable to shareholders after deducting non-recurring gains and losses projected to increase by approximately 41.33%, 102.65%, and 32.56% year-on-year, respectively [1]

Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, with basic earnings per share doubling to 6.70 CNY per share [1] Group 1: Financial Performance - The company achieved historical highs in revenue and profit across three metrics for the fiscal year 2025 [1] - The expected net profit attributable to shareholders for 2025 is projected to lead to a record cash dividend of over 5.7 billion CNY [1] Group 2: Shareholder Returns - WuXi AppTec has maintained a leading cash dividend ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The anticipated rapid growth in net profit will be shared with shareholders through cash dividends [1] Group 3: Incentive Plans - The company has met the core unlocking conditions for its 2025 H-share incentive trust plan, with revenue targets set at 42 billion CNY and 43 billion CNY for additional stock grants [1] - A total of 2.5 billion HKD in equity incentives is set to be unlocked, aimed at fostering long-term development with core talent [1]

Core Viewpoint - WuXi AppTec has announced a significant increase in both revenue and profit for the fiscal year 2025, indicating strong operational performance and growth potential [1] Financial Performance - The company expects total revenue of approximately 45.456 billion yuan, representing a year-on-year growth of 15.84% [1] - Revenue from continuing operations is projected to grow by 21.4%, showcasing robust development in its core business [1] - Key profit indicators have also seen substantial year-on-year increases, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit after deducting non-recurring items growing by 41.33%, 102.65%, and 32.56% respectively [1] - Overall, WuXi AppTec's revenue and three major profit metrics are set to surpass historical peaks, highlighting a trend of high-quality growth [1]

北京商报讯（记者 王寅浩 宋雨盈）1月12日，药明康德发布2025年度业绩预增公告，公司预计2025年实 现营业收入约454.56亿元，同比增长约15.84%；实现经调整归母净利润约149.57亿元，同比增长约 41.33%；实现归属于公司股东的净利润约191.51亿元，同比增长约102.65%。 ...

附："2025中国企业ESG百强"榜 新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点 击查看【 ESG评级中心服务手册】 在全球可持续发展浪潮席卷而来的当下，ESG（环境、社会、公司治理）已成为衡量企业高质量发展的核心标尺，更是连接企业价值与社会价值的关键纽 带。随着国内ESG生态体系的加速完善，政策监管持续收紧、资本市场对ESG表现的关注度不断飙升，企业的可持续发展能力愈发成为其核心竞争力的重 要组成部分。 在此行业背景下，新浪财经重磅发布"2025中国企业ESG百强"榜单。该榜单依托新浪财经专业的ESG评级体系，以5000余家A股上市公司及在港上市内地 企业为评价对象，创新性搭建18套行业ESG评价模型，纳入150余项ESG指标，通过量化模型综合演算，对企业ESG表现进行全面、客观的综合评价，最 终筛选出中国ESG实践的标杆企业。榜单不仅为行业树立了发展典范，更为投资者提供了极具参考价值的决策依据。 药明康德在环境、社会、公司治理领域开展了大量工作，积累了丰富的创新实践与扎实的落地成果。凭借在ESG各领域的卓越表现，药 ...